Filtration Leader’s Advanced BioScience Capability Showcased at COMPAMED

One of the world’s leading producers of high performance filtration and separation technology will be showcasing its advanced materials for the bioscience market at this year’s COMPAMED Exhibition in Dusseldorf, Germany.

Porvair Filtration Group - recently honoured with the Queen’s Award for Enterprise in International Trade - will be on Stand F08 in Hall 08A, 16-19 November, where it will showcase a new 96-well microplate-based chromatin immunoprecipitation (ChIP) product in addition to the existing range of Chromatrap® ChIP kits, enzymatic shearing and DNA clean-up kits.

The Chromatrap® solid-state ChIP assays are faster, more sensitive and require less input chromatin. The result is a quick, easy and sensitive protocol for producing high-purity DNA fragments which may be used for qPCR or sequencing.

The new Chromatrap® 96-well ChIP assay is ideal for automation of multiple transcription factor assays. Porvair‘s unique patented technology provides superior well-to-well reproducibility and rapid analysis. This novel product, incorporating Porvair’s BioVyon™ technology, has been a joint development between Porvair Filtration Group, Porvair Sciences and the University of Swansea.

In addition Porvair will be presenting its BioVyon™ range of materials and products for use in a wide variety of analytical, medical and pharmaceutical applications, offering more sensitive analysis, better healthcare, improved medical knowledge and faster diagnosis and treatment of diseases.

BioVyon™ is a highly versatile range of porous plastics which can be employed in a wide range of functions across the medical sector. The requirements of materials for these market sectors are usually far more stringent than those for industrial applications. They need to be contamination-free with very low levels of leachables and with full traceability. Regulatory approval is also an essential prerequisite for many products in these sectors.

Porvair not only manufacture the BioVyon™ materials but can assemble finished products to the standards demanded by these regulated markets.

Porvair’s facility in Wrexham has recently invested in the plant and processes required to manufacture complete finished devices in the market for Solid Phase Extraction (SPE). This capability allows the business to offer its customers the complete service for products incorporating Porvair’s state-of-the-art porous materials.

It is expected to become a significant cornerstone of the company’s progression from a manufacturer of porous materials, to a manufacturer of finished products. The equipment is suitable for use in cleanroom environments and can also be utilised for a host of applications, including diagnostics, analytical, and synthesis products.

General Manager at Porvair’s Wrexham division, Roy Rigby said: “Since 2007 the BioVyon™ range of materials has continued to expand and is being used in such applications as drug filtration and purification, catheter vents, bone cement mixing in the operating theatre and nasal spray filters. Now, with BioVyon™ being coupled to biomolecules such as Protein A or G, and antibodies too, a whole range of possibilities have opened up. The new exciting range of CHIP products illustrates our growing capability and ambition.”

“Our scientists have been genuinely excited by the opportunities that they have helped to realise in the laboratory that can then be implemented for wide healthcare benefits, the refinement of medical knowledge, and in the diagnosis and treatment of disease.

“Furthermore, our new automated assembly machinery is redefining how Porvair approaches the bioscience side of the business, ensuring higher quality products and a much stronger manufacturing focus. Indeed, this will have major strategic implications for Porvair, driving improvements across a wide range of applications, offering not only the manufacture of our BioVyon™ materials but the ability to manufacture the finished product to the regulatory standards demanded by the Life Science and analytical markets”